Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9996084 | 0.99 | TBXAS1 (0.61) | TBXAS1HMOX2 | |
| SCHEMBL410597 | 0.91 | HMOX2 (0.61) | TBXAS1HMOX2 | |
| Hydrochloric Acid SCHEMBL411563 | 0.90 | TBXAS1 (0.59) | TBXAS1HMOX2 | |
| SCHEMBL8803470 | 0.86 | PLA2G4A (0.59) | TBXAS1 | |
| SCHEMBL8805267 | 0.86 | CYP19A1 (0.63) | TBXAS1 | |
| SCHEMBL8803506 | 0.86 | TBXAS1 (0.56) | TBXAS1 | |
| SCHEMBL8803483 | 0.86 | TBXAS1 (0.60) | TBXAS1 | |
| SCHEMBL8803240 | 0.83 | TBXAS1 (0.53) | TBXAS1 | |
| SCHEMBL8804155 | 0.83 | PLA2G4A (0.61) | TBXAS1 | |
| SCHEMBL11238973 | 0.82 | HMOX2 (0.64) | TBXAS1HMOX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | disclosed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | disclosed |
| EP-0492474-B1 | 1,3-Dioxolane derivatives as cholesterol-lowering agents | SYNTEX INC (US) | 1997-03-05 | — | — | EP | disclosed |
| US-5158949-A | 1,3-DIOXOLANE DERIVATIVES AS CHOLESTEROL-LOWERING AGENTS | SYNTEX (U.S.A.) INC. (US) | 1992-10-27 | — | — | US | disclosed |
| EP-0492474-A1 | 1,3-Dioxolane derivatives as cholesterol-lowering agents | SYNTEX (U.S.A.) INC. (US) | 1992-07-01 | — | — | EP | disclosed |
| US-4359475-A | SPERMICIDES, MICROBIOCIDES OR ANTICONVULSANTS | SYNTEX (U.S.A.) INC. (US) | 1982-11-16 | — | — | US | disclosed |
| EP-0049565-A2 | Derivatives of substituted N-alkylimidazoles, their preparation and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1982-04-14 | — | — | EP | disclosed |
| US-4321272-A | Derivatives of substituted N-alkylimidazoles | SYNTEX (U.S.A.) INC. (US) | 1982-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | TXNRD2, HMOX1, HMOX2 | TBXAS1 469/4885HMOX2 3/4885 |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | TBXAS1 1071/4885HMOX2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.